Botulinum toxin type A in prophylactic treatment of migraine headaches: A preliminary study

被引：5

作者：

Nelson Barrientos

Pedro Chana

机构：

[1] Dipreca Hospital, Santiago

来源：

The Journal of Headache and Pain | 2003年 / 4卷 / 3期

关键词：

Botulinum toxin type A; Double blind; Migraine; Placebo control; Prophylaxis;

D O I：

10.1007/s10194-003-0049-2

中图分类号：

学科分类号：

摘要：

The purpose of this study was to determine the safety and efficacy of botulinum toxin type A (BOTOX; Allergan, Irvine, USA) in migraine prophylaxis. We performed a double-blind, randomized, 90-day placebo-controlled study that enrolled 30 adult migraineurs. Patients received 50 units botulinum toxin type A (n=15) or placebo (n=15). Outcome measures were monthly frequency and duration of migraine attacks and the number of severe attacks. Botulinum toxin type A produced significantly greater reductions in the frequency of migraine attacks of any severity at Day 90 (-3.14 vs. - 0.53; p<0.05) and in the frequency of severe migraine attacks at Days 60 (- 1.4 vs. -0.54; p<0.05) and 90 (-1.8 vs. -0.20; p<0.02). One patient in the botulinum toxin type A group experienced mild, transient frontalis muscle weakness lasting approximately 30 days. Botulinum toxin type A injections were well tolerated and provided effective migraine prophylaxis in these patients.

引用

页码：146 / 151

页数：5

共 21 条

[1]

Stewart W.F., Lipton R.B., Celentano D.D., Reed M.L., Prevalence of migraine in the United States, JAMA, 267, pp. 64-69, (1992)

[2]

Lipton R.B., Stewart W.F., Diamond S., Diamond M.L., Reed M., Prevalence and burden of migraine in the United States: Data from the American Migraine Study II, Headache, 41, pp. 646-657, (2001)

[3]

Lipton R.B., Diamond S., Reed M., Diamond M.L., Stewart W.F., Migraine diagnosis and treatment: Results from the American Migraine Study II, Headache, 41, pp. 638-645, (2001)

[4]

Hu X.H., Markson L.E., Lipton R.B., Stewart W.F., Berger M.L., Burden of migraine in the United States, Arch. Intern. Med., 159, pp. 813-818, (1999)

[5]

Silberstein S.D., Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 55, pp. 754-763, (2000)

[6]

Simpson L.L., The origin, structure, and pharmacological activity of botulinum toxin, Pharmacol. Rev., 33, 3, pp. 155-188, (1981)

[7]

Borodic G.E., Acquadro M., Johnson E.S., Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects, Expert Opin. Invest. Drugs, 10, 8, pp. 1531-1544, (2001)

[8]

Jost W.H., Kohl A., Botulinum toxin: Evidence-based medicine criteria in blepharospasm and hemifacial spasm, J. Neurol., 248, SUPPL. 1, pp. 21-24, (2001)

[9]

Tintner R., Jankovic J., Botulinum toxin for the treatment of cervical dystonia, Expert Opin. Pharmacother., 2, 12, pp. 1985-1994, (2001)

[10]

Esquenazi A., Mayer N., Botulinum toxin for the management of muscle overactivity and spasticity after stroke, Curr. Atheroscler. Rep., 3, 4, pp. 295-298, (2001)

← 1 2 3 →